Welcome to our dedicated page for Biolase news (Ticker: BIOLQ), a resource for investors and traders seeking the latest updates and insights on Biolase stock.
The BIOLASE INC (BIOLQ) news page on Stock Titan aggregates company-related coverage tied to BIOLASE, which describes itself as the world's leading innovator in dental laser technology. News items highlight its role in the medical devices and dental technology space, with a focus on minimally invasive laser dentistry and patient-centered clinical outcomes.
Recent company communications emphasize BIOLASE’s participation in major dental and periodontal conferences, where it showcases Er,Cr:YSGG laser technology and all-tissue laser systems. Articles describe featured lectures on advancing laser solutions for periodontal and implant health, as well as novel YSGG laser-assisted protocols for periodontitis treatment aimed at predictable pocket elimination, bacterial decontamination, and precise osseous contouring.
Other news covers live demonstrations of Waterlase-branded systems at professional meetings, along with educational sessions for clinicians interested in integrating laser technology into their practices. Company statements also discuss clinical research findings related to bleeding, swelling, postoperative comfort, and procedure efficiency when using its laser platforms.
In addition, the news flow includes corporate developments, such as BIOLASE’s acquisition by MegaGen Implant and the company’s description of this transition as a revitalization and new chapter under different ownership. Investors, clinicians, and observers can use this page to review how BIOLASE presents its technology, clinical protocols, educational initiatives, and ownership changes over time.
BIOLASE (NASDAQ:BIOL) will participate in the 2025 Greater New York Dental Meeting (GNYDM) in New York City, November 28–December 3, 2025.
On Sunday, November 30, 2025, 10:00 AM–12:30 PM, Philip Kang, DDS, will present “Advancing Laser Solutions for Periodontal and Implant Health” on the GNYDM Main Stage for 3 CE credits, focusing on Er,Cr:YSGG (YSGG) laser technology, clinical advantages, patient comfort, and practice growth.
Visit Booth #4129 for hands-on demos of Waterlase iPlus and exclusive show-only pricing.
BIOLASE (NASDAQ:BIOLQ) will present a new Er,Cr:YSGG YSGG laser resective protocol for treating periodontitis at the American Academy of Periodontology (AAP) 2025 Corporate Forum in Toronto, Oct 15–18.
The featured session by Philip Kang, DDS on Oct 15 at 2:05 PM describes a standardized, minimally invasive approach aiming for predictable pocket elimination, effective bacterial decontamination, and precise osseous contouring. BIOLASE will demonstrate the Waterlase iPlus Premier Edition at Booth #1004 with hands-on demos and giveaways. The release cites a blind McGuire Institute study in the Journal of Periodontology reporting less bleeding/swelling, faster procedures, and superior patient-reported outcomes versus open flap techniques.
BIOLASE (NASDAQ:BIOLQ), the global leader in dental laser technology, has been acquired by MegaGen Implant, marking a significant transformation for the company. Under the leadership of new CEO Dr. Kwang Bum Park, founder of MegaGen Implant, BIOLASE aims to overcome recent operational challenges and restore its market position.
The merger combines BIOLASE's pioneering dental laser systems, including Waterlase™, with MegaGen's expertise in implantology. MegaGen, established in 2002 by over 70 dentists, has become South Korea's leading dental implant exporter. This strategic acquisition promises enhanced service systems, increased investment, and improved training support for BIOLASE's global customer base.
FAQ
What is the current stock price of Biolase (BIOLQ)?
What is the market cap of Biolase (BIOLQ)?
